



Published in final edited form as:

*Pancreatology*. 2016 ; 16(5): 692–693. doi:10.1016/j.pan.2016.08.002.

## Acceleration of our understanding of recurrent acute and chronic pancreatitis

**Stephen J. Pandol<sup>a,\*</sup>, Chris E. Forsmark<sup>b</sup>, and Phil A. Hart<sup>c</sup> on behalf of The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)**

<sup>a</sup>Cedars-Sinai Medical Center, University of California and Department of Veterans Affairs, Los Angeles, CA, USA

<sup>b</sup>University of Florida, Gainesville, FL, USA

<sup>c</sup>Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA

---

Whitcomb et al. [1] present a new framework for describing chronic pancreatitis in an attempt to shift our definition of the disease from a purely morphologic one to one that incorporates disease mechanisms. This is an important step that is absolutely needed for the field to progress. Clinicians and clinical investigators interested in chronic pancreatitis have long been hamstrung by the lack of consensus in diagnostic criteria. This has led to numerous, and often conflicting, deeply held opinions and approaches to this syndrome. Their paper reviews the historical attempts to define this disease illustrating that our limited understanding of pathogenesis led to descriptions largely limited to morphologic classifications. This approach, inevitably, led to diagnostic criteria that were best suited to identify far-advanced disease, but unable to identify disease at an earlier stage. Early detection is necessary for any effective therapy to be applied to mitigate or reverse the process.

Important to this discussion, there have been significant advances since many previous classifications were devised such as an improved understanding of the effects of genetic mutations [2] and environmental factors such as smoking and obesity [3] in the pathogenesis of chronic pancreatitis. Furthermore, there continues to be a rapidly evolving understanding of the pathogenesis of pancreatic disease. As an example, findings reported in the exocrine pancreas in patients with diabetes [4] show that diabetes can promote fibrosis with minimal effects on inflammation, which has been termed “diabetic exocrine pancreatopathy.” Another example is a recent publication [5] showing that alcohol abuse causes abnormal expression of cystic fibrosis transmembrane conductance regulator (CFTR), which is necessary for pancreatic fluid secretion and when mutated results in chronic pancreatitis morphology. This finding indicates that the deleterious effects of alcohol abuse occur in the ductal epithelium as well as the acinar cell, and both functional components of the exocrine pancreas are in an interplay underlying disease pathogenesis [6].

---

\*Corresponding author. Stephen.Pandol@cshs.org (S.J. Pandol).

A shift to add mechanistic determinants to our definitions of recurrent acute and chronic pancreatitis will also promote the identification and addition of key cellular systems and immune systems that are altered in these diseases. The pancreas is unique with its highly developed protein synthesizing and transport systems. Animal models of pancreatitis demonstrate that disturbances in regulation of calcium signals [7]; protein processing for export in the endoplasmic reticulum and endo-lysosomal system [8,9]; and mitochondrial function [10,11] lead to pancreatitis responses. This is facilitated by critical immune responses in these models, responses that are relevant to human disease [12]. Although these examples of cellular and immune system alterations in experimental models are useful, what is lacking is information about how they are differentially affected by diverse stimuli or combinations of stimuli. Importantly, we lack biomarkers of these pathobiologic responses in humans. This lack of information is a hindrance to development of therapeutics for recurrent acute and chronic pancreatitis.

In the paper by Whitcomb et al. [1], a prolonged process was required to reach the eventual proposed definition. The definition provides, in our opinion, a valuable starting point for the entire pancreas community to build on. The definition connects many essential concepts about chronic pancreatitis, and importantly recognizes the need for additional attention to the early stages of disease. This focus is needed for us to achieve what our patients need, prompt and accurate diagnosis, comprehensive assessment of risk factors and etiologies, and effective intervention to improve quality (and quantity) of life.

In one response to these knowledge gaps, the National Institutes of Health in the United States has initiated The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). This consortium involves a group of 10 investigative sites and one coordinating center in the United States charged with undertaking a comprehensive clinical, epidemiological, and biological characterization of patients with recurrent acute and chronic pancreatitis to gain insight into the pathophysiology of these diseases and potential complications including chronic pain, exocrine pancreatic insufficiency, type 3c diabetes mellitus, and pancreatic cancer.

A key objective of this initiative is to further delineate the mechanisms of this disease, which will inform and permit subsequent improvements to the definition of chronic pancreatitis.

## Acknowledgments

### Grant support

Research reported in this publication was supported by National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award numbers U01DK108314, U01DK108320, and U01DK108327. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## References

1. Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. *Pancreatology*. 2016; 16:218–24. [PubMed: 26924663]

2. Whitcomb DC. Genetic risk factors for pancreatic disorders. *Gastroenterology*. 2013; 144:1292–302. [PubMed: 23622139]
3. Alsamarrai A, Das SL, Windsor JA, Petrov MS. Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. *Clin Gastroenterol Hepatol*. 2014; 12:1635–44. e1635. quiz e1103. [PubMed: 24509242]
4. Mohapatra S, Majumder S, Smyrk TC, Zhang L, Matveyenko A, Kudva YC, et al. Diabetes mellitus is associated with an exocrine pancreatopathy: conclusions from a review of literature. *Pancreas*. 2016
5. Maléth J, Balázs A, Pallagi P, Balla Z, Kui B, Katona M, et al. Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. *Gastroenterology*. 2015; 148:427–39. e416. [PubMed: 25447846]
6. Hegyi P, Pandol S, Venglovecz V, Rakonczay Z. The acinar-ductal tango in the pathogenesis of acute pancreatitis. *Gut*. 2011; 60:544–52. [PubMed: 20876773]
7. Sutton R, Petersen OH, Pandol SJ. Pancreatitis and calcium signaling: report of an international workshop. :2008e1–14.
8. Sah RP, Garg SK, Dixit AK, Dudeja V, Dawra RK, Saluja AK. Endoplasmic reticulum stress is chronically activated in chronic pancreatitis. *J Biol Chem*. 2014; 289:27551–61. [PubMed: 25077966]
9. Lugea A, Waldron RT, Pandol SJ. Pancreatic adaptive responses in alcohol abuse: role of the unfolded protein response. *Pancreatology*. 2015; 15:S1–S5. [PubMed: 25736240]
10. Mukherjee R, Mareninova OA, Odinkova IV, Huang W, Murphy J, Chvanov M, et al. Unit aNPBR. Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. *Gut*. 2016; 65:1333–46. [PubMed: 26071131]
11. Shalbueva N, Mareninova OA, Gerloff A, Yuan J, Waldron RT, Pandol SJ, et al. Effects of oxidative alcohol metabolism on the mitochondrial permeability transition pore and necrosis in a mouse model of alcoholic pancreatitis. *Gastroenterology*. 2013; 144:437–46. e436. [PubMed: 23103769]
12. Xue J, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol SJ, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. *Nat Commun*. 2015; 6:7158. [PubMed: 25981357]